Tomivosertib (eFT-508)
Phase 1/2Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma
Conditions
Lymphoma
Trial Timeline
Feb 8, 2017 → Apr 4, 2019
NCT ID
NCT02937675About Tomivosertib (eFT-508)
Tomivosertib (eFT-508) is a phase 1/2 stage product being developed by eFFECTOR Therapeutics for Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02937675. Target conditions include Lymphoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03616834 | Phase 2 | Completed |
| NCT02937675 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AFM13 | Affimed | Phase 2 | 44 |
| Pirtobrutinib + Brexucabtagene Autoleucel | Eli Lilly | Phase 2 | 52 |
| Enzastaurin | Eli Lilly | Phase 2 | 52 |
| Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + Dexamethasone | Eli Lilly | Phase 2 | 52 |
| Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) | Eli Lilly | Phase 2 | 52 |
| VIP152 + BTKi | Vincerx Pharma | Phase 1 | 25 |
| Nanatinostat in combination with valganciclovir | Viracta Therapeutics | Phase 2 | 44 |
| Sepantronium Bromide | Cothera Bioscience | Phase 2 | 44 |
| Copanlisib + Rituximab | Celltrion | Phase 2 | 52 |
| Rituximab + Pembrolizumab | Celltrion | Phase 2 | 52 |
| Rituximab + Methotrexate + Cytarabine Injection | Celltrion | Phase 2 | 52 |
| rituximab | Celltrion | Phase 1 | 33 |
| CT-P10 + Rituxan | Celltrion | Phase 3 | 77 |
| Rituxan + CT-P10 + Cyclophosphamide + Vincristine + Prednisone | Celltrion | Phase 3 | 77 |
| Rituximab, lenalidomide | Celltrion | Phase 2 | 52 |
| Rituximab + Lenalidomide + Valemetostat | Daiichi Sankyo | Phase 1/2 | 41 |
| Valemetostat tosylate | Daiichi Sankyo | Phase 2 | 52 |
| PLX3397 | Daiichi Sankyo | Phase 2 | 52 |
| Valemetostat Tosylate | Daiichi Sankyo | Phase 2 | 52 |
| HMPL-689 | HUTCHMED | Phase 1 | 28 |